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Abstract
Background: The Shc isoforms is known to mediate immune responses and has been indicated as a negative
regulator of autoimmunity and lymphocyte activation. We aimed to evaluate the immune-regulatory role of Shc in
rat bone marrow-derived DCs in the maturation process triggered by LPS.
Results: We found that, in response to LPS, expression of Shc proteins was induced and that neutralization of Shc
inhibited the LPS-induced transient phosphorylation of p52Shc on pTyr239/240 in DCs of Lewis (LEW; RT1
l) rats.
Moreover, the significantly enhanced expression of IL-10 and the surface level of costimulatory molecule CD80, as
well as suppressed expression of IL-6 and IL-12 in the Shc-silenced DCs were also observed. Similar IB
phosphorylation occurred in Shc-silenced DCs primed by LPS, indicating Shc is not associated with NF-B pathway.
We further demonstrate that Shc blockade on LPS-treated DCs results in significant increase of the overall STAT3
phosphorylation and the relative levels of phospho-STAT3 in the nuclear fraction. STAT3 activation by LPS with or
without Shc blockade was totally abolished by SU6656, a selective Src family kinases inhibitor, underscoring the
critical role of Src-mediated activation.
Conclusions: We conclude that Shc blockade in LPS-primed DC leads to the development of tolerogenic DC via
Src-dependent STAT3 activation and that adaptor protein Shc might play a pivotal role in mediating immunogenic
and tolerogenic properties of DCs.
Background
Dendritic cells (DCs) are the most important APC that
play a crucial role in bridging innate resistance and
adaptive immunity [1,2]. Immature DCs reside in per-
ipheral tissues, where they release soluble mediators
(cytokines, chemokines and IFNs) that participate in
innate inflammatory responses during infection [2,3].
Upon capturing antigens, DCs migrate to the lymph
nodes and present processed antigenic epitopes to T
cells, resulting in their activation and further expansion
[4,5]. A variety of signals induce DC maturation. Mature
DCs express high levels of antigen presenting and co-sti-
mulatory molecules and certain cytokines critical for the
nature of the T cell response. For instance, Th1-type T
cell responses need inflammatory IL-12 produced by
DCs. Conversely, DCs can also produce anti-inflamma-
tory cytokines, such as IL-10 [6-8], which influences the
DC maturation process by down-regulating IL-12 pro-
duction and thus interfering with the Th1-type T cell
responses [4,9-11]. Moreover, IL-10-producing DCs also
promote immune tolerance by modulating the suppres-
sive effects of regulatory T cells [12,13]. Accordingly,
there has been considerable interest in influencing the
DC maturation process to direct T cell responses to a
desired type (i.e., Th1 vs. Th2/3) for translational
purposes.
A useful system for the study of DCs in culture is the
use of monocyte-derived DCs obtained in vitro by GM-
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+ mono-
cytes. These cells can produce high amounts of cyto-
kines such as IL-6 and IL-12 when stimulated with LPS
[14]. Some evidence suggests an involvement of Src-
family tyrosine kinases (SFKs) in the signaling pathway
triggered by LPS. In monocytes, LPS activates the Src-
family kinase Lyn associated with CD14, a glycosyl
phosphatidylinositol (GPI)-anchored molecule that
cooperates with toll-like receptor 4 (TLR4) in LPS bind-
ing on the surface of these cells [15]. However, the com-
plexity in the engagement of TLRs by LPS leading to
interactions with intracellular adaptor proteins and their
associated kinases is still under investigation.
Shc adaptor proteins are substrates of receptor tyro-
sine kinases, and signal events initiated by their phos-
phorylation culminate in Erk and Jnk activation [16,17].
Among the three related Shc genes, ShcA is ubiqui-
tously expressed, whereas ShcB and ShcC are restricted
to cells of neural origin, and we describe ShcA here as
Shc based on this tissue restriction. Shc is expressed as
three isoforms of 46, 52 and 66 kDa derived from ShcA
via post-transcriptional splicing, which display the PTB-
CH1-SH2 Shc family signature, with an added N-term-
inal CH2 domain in p66ShcA and a truncated PTB
domain in p46ShcA. The PTB and SH2 domains both
bind tyrosine-phosphorylated peptides and associate
with activated receptor kinases [18]. Recently, it has
been found that the defects of pp66ShcA in T cells of
p66ShcA
-/- mice display enhanced proliferative
responses to T-cell antigen receptor (TCR) agonists,
suggesting a potential role of p66ShcA in lymphocyte
homeostasis [19]. The p66ShcA
-/- mice also develop a
lupus-like autoimmune disease, which implies a possible
key role of p66ShcA in regulating immunologic toler-
ance and the development of systemic autoimmunity.
However, there has been no definite evidence of a role
for Shc proteins in DC maturation, cytokine production
or the expression of co-stimulatory molecules triggered
by LPS.
In the present study, we briefly address the role of Shc
proteins in the maturation process triggered by LPS in
rat bone marrow-derived DCs, and we evaluate their
contribution in the context of LPS-induced TLR4
signaling.
Results
Transient activation and sustained induction of Shc
proteins
To test whether LPS can activate Shc, bone marrow-
derived DCs were treated with 0.5 μg/ml LPS for 48 hrs.
When dendritic cells obtained from LEW rats were cul-
t u r e dw i t hr G M - C S Fa n dr I L - 4 ,p 4 6 S h ca n dp 5 2 S h c
were expressed in immature DCs, but the inducible
form of p66Shc was not observed, as shown by Western
blot analysis (Figure 1A). At 48 h after the addition of
endotoxin, the expression of p66Shc was induced, and
the accumulation of p52Shc was also increased. How-
ever, no significant change was observed in p46Shc
accumulation.
Shc phosphorylation mechanisms were also examined
in the LPS-induced maturation of DCs. Figure 1B shows
that p52Shc protein was transiently phosphorylated on
tyrosine residues 239/240 but not 317. We further eval-
uated whether the addition of anti-Shc mAb could block
the phosphorylation events of Shc in DCs exposed to
LPS. As shown in Figure 1B, the LPS-induced transient
phosphorylation of Shc protein in YY239/240 was
down-regulated by 24-h preincubation of anti-Shc
monoclonal antibody. This result suggests that the anti-
Shc mAb we used could act as a blocking antibody for
S h cn e u t r a l i z a t i o n .M o r e o v e r ,w ee v a l u a t e dt h er o l eo f
non-receptor Src-family kinases (SFKs) in Shc phos-
phorylation by using a small molecule Src-family kinase
inhibitor SU6656 while DCs was exposed to LPS. The
inhibition of Shc phosphorylation by SU6656 indicating
the involvement of SFKs activity in LPS-triggered Shc
signaling events. Therefore, tyrosine phosphorylation on
positions 239/240 of Shc is Src-dependent.
Effect of Shc silencing on the response of DCs to LPS
exposure
To evaluate the role of Shc proteins in DC cytokine pro-
duction, a neutralizing anti-Shc mAb was added to
immature DCs, which concomitantly treated with LPS
for 24 h. As shown in Figure 2, incubation of DCs with
anti-Shc mAb but not with control mouse IgG in the
presence of LPS for 24 h elicited a lower level of IL-6
secretion (Figure 2A). To determine whether the endo-
g e n o u sS h cd i r e c t l yi n v o l v e d in LPS-induced IL-6 pro-
duction, the Shc siRNA was used. Shc siRNA dose-
dependently inhibited the expression of Shc mRNA
expression (Figure 2B). Figure 2C also shows that LPS-
induced IL-6 production was inhibited by Shc siRNA.
Decreased secretion of IL-6 by 2.5-fold in DCs stimu-
lated with LPS and concomitantly with transfected Shc
siRNA (Figure 2C).
In addition to IL-6, LPS induces DC production of
various cytokines, including IL-10 and IL-12. Therefore,
the homeostasis of inflammation versus immune sup-
pression controlled by DCs via the balance of produced
cytokines would be crucial, so we determined the role of
Shc in IL-10 and IL-12 secretion. DCs were treated with
LPS (0.5 μg/ml) for 24 h in the presence of transfected
Shc siRNA (50 nM) or NEG. siRNA (50 nM), and the
secretion of IL-10 and IL-12p70 in the supernatant were
measured by ELISA. The mRNA expression of IL-10
and IL-12p40 was also determined by quantitative RT-
PCR. We found that LPS induced substantial secretion
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Page 2 of 12Figure 1 LPS stimulates Shc protein accumulation and activation in bone marrow-derived DCs. Purified DCs were stimulated with LPS (0.5
μg/ml), and Shc protein accumulation was measured at 48 h (A). For Shc activation, DCs were treated with LPS (0.5 μg/ml) with mouse control
IgG or anti-Shc mAb (2 μg/ml) for 10 or 30 min, or with LPS (0.5 μg/ml) in the presence of 10 nM SU6656 and/or mouse control IgG (2 μg/ml)
for 10 min, as indicated (B). Cell lysate (30 μg) from each sample was subjected to Western blot with anti-Shc, anti-phosphotyrosine 317-Shc
(pTyr317-Shc) and anti-phosphotyrosine 239/240-Shc (pTyr239/240-Shc) mAb. The bound antibodies were detected by the ECL system. The
significant change of pTyr239/240-Shc was observed and the statistics at 10-min was presented. The results are representative of three
independent experiments. (n = 3; **, P < 0.01)
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Page 3 of 12Figure 2 Effects of Shc blockade on the secretion and mRNA expression of IL-6, IL-10 and IL-12 in DC maturation. Purified DCs were
cultured with or without anti-mouse Shc mAb at various concentrations, as indicated, and stimulated with LPS (0.5 μg/ml) for 24 h and the IL-6
secretion was measured in triplicate supernatants by ELISA (A). DCs were transfected with Shc siRNA or negative control siRNA (NEG. siRNA) as
described in the Materials and Methods. Quantitation of the RNAi efficiency for Shc silencing was analyzed by quantitative PCR to confirm the
blockade effect of the Shc siRNA 24 h after transfection (B). The relative expression levels of IL-6 mRNA were measured in BMDCs stimulated by
LPS in the absence or presence of Shc siRNA (50 nM), or NEG. siRNA (50 nM) for 24 h. Cells were collected, RNA was isolated, and IL-6 mRNA
was determined by RT-PCR (C). Moreover, the amount of IL-10 and IL-12 were also determined by ELISA and RT-PCR. The data show enhanced
secretion and mRNA level of IL-10 (D, E) and reduced production of IL-12 (F, G) from DCs in the presence of Shc siRNA. Each column represents
the mean ± SE of the three independent experiments (n = 3; *, P < 0.05; **, P < 0.01).
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Page 4 of 12of IL-10 and increased expression of IL-10 mRNA by
DCs. Notably, the LPS-induced production of IL-10 was
significantly enhanced in the presence of Shc siRNA
(Figure 2D and 2E). In contrast, cultured DCs showed
vigorous secretion of IL-12p70 and mRNA expression of
IL-12p40 in response to LPS treatment, while the IL-12
levels were significantly suppressed by Shc siRNA (Fig-
ure 2F and 2G). Therefore, Shc-mediated signaling
appears to be crucial for regulation of IL-10 and IL-12
production by DCs upon LPS stimulation.
Enhanced expression of T cell co-stimulatory molecule
CD80 on Shc-silenced DCs in response to LPS exposure
DCs undergo a maturation process while the host
detects a microbial infection, which enhances their abil-
ity to process and present exogenous antigen. Optimal
antigen presentation of DCs requires the expression of
specific membrane protein markers. Maturation of DCs
is associated with profound changes in the surface phe-
notype of protein markers, including an up-regulated
expression of co-stimulatory and MHC class II mole-
cules [20,21]. During maturation, the co-stimulatory
molecules (CD80, CD86) are required for T cell priming
and produce cytokines that direct T cell differentiation,
whereas processed antigen fragments are present to the
surface using MHC-II molecules. In order to evaluate
the effects of Shc blockade on co-stimulatory and MHC
class II molecules during DC maturation, the immature
DCs were transfected with Shc siRNA prior to LPS
treatment and the surface protein expression was mea-
sured by flow cytometry. CD80, CD86 and MHC-II pro-
tein levels were increased significantly in DCs expose to
LPS for 24 h. Moreover, we found that DCs treated with
LPS for 24 h with transfected Shc siRNA display
e n h a n c e dl e v e lo fC D 8 0( P<0 . 0 5 ) ,b u tn o tC D 8 6o r
MHC-II (Figure 3), indicating that CD80 was selectively
enhanced during LPS-triggered maturation with Shc
blockade.
LPS-induced STAT3 phosphorylation and nuclear
translocation are highly enhanced by Shc silencing in DCs
We further investigated STAT3 phosphorylation in LPS-
induced DCs with or without Shc blockade. As shown
in Figure 4, STAT3 was highly phosphorylated at 6 h in
LPS-stimulated DCs, and its phosphorylation was almost
down to basal after 24 h. The phosphorylation level of
STAT3 was significantly enhanced in DCs transfected
with Shc siRNA but not NEG. siRNA. Moreover, the
involvement of LPS-induced IL-10 secretion was also
examined by using IL-10 neutralizing antibody (Figure
5). Our data suggests the LPS-induced STAT3 activation
and the enhanced STAT3 activation via Shc blockade
are IL-10 dependent. Furthermore, SU6656 totally abol-
ished the induced STAT3 phosphorylation indicating
the involvement of SFKs activity in STAT3 activation of
LPS-stimulated DCs.
The nuclear translocation of phospho-STAT3 was
measured. As shown in Figure 6, Shc blockade promotes
nuclear localization of phospho-STAT3. STAT3 was
detected mainly in the cytosolic fraction of DCs with a
variety of treatment conditions. The relative phosphory-
lation levels of STAT3 in both cytosolic and nuclear
fractions were increased by LPS treatment for 6 h.
Moreover, the relative phosphorylation level of STAT3
in the nuclear fraction (N) but not in the cytosol (C)
was highly enhanced by LPS treatment with Shc block-
ade. This result indicates that more STAT3 phosphory-
lated on Tyr-705 is generated into the nucleus in LPS-
induced DCs with Shc blockade. The activation of
STAT3 by LPS with or without Shc blockade was totally
abolished by SU6656 both in N and C fractions.
Discussion
We show that expression of Shc proteins was induced
by LPS and that Shc blockade inhibited LPS-primed
phosphorylation of p52Shc on tyrosine residues. IL-6
and IL-12 production triggered by LPS were suppressed
by Shc blockade. Moreover, the expressions of costimu-
latory molecule CD80 and of IL-10 were enhanced
while silencing endogenous Shc on LPS-induced DCs.
However, the LPS-induced IL-10 production would be
totally abolished in the presence of SU6656, implying
that the signals transducing via adaptor protein Shc
negatively regulate the IL-10 expression and underscor-
ing the complexity of the role of SFKs.
Adaptive immunity evolved from an ancient innate
defense mechanism common to most microorganisms.
Therefore, it is not surprising that sensing and signal
transduction in innate immunity is the starting point
of the specific immune response. APCs, such as
macrophages/monocytes and DCs, activated by various
antigens of bacteria [22,23] and other microorganisms
[24-26] through Toll-like receptors (TLRs), could be
central to this process that integrates innate informa-
tion and conveys it to lymphocytes [27]. Adaptor pro-
teins differ from other signaling molecules in their lack
of inherent catalytic activity, but they are primarily
composed of modular domains that bind and act as
scaffolds for the organization of macromolecular com-
plexes, and they recruit other signaling proteins for
correct localization. They play important roles in the
integration and propagation of signals that lead to lym-
phocyte development and homeostasis [28]. Therefore,
the mechanisms underlying TLR-mediated activation
of APCs have been extensively analyzed, but the down-
stream signaling pathways governing the release of
inflammatory mediators in response to LPS are yet to
be understood.
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inflammatory cytokines requires the recruitment of
intracellular adaptor molecules. For example, myeloid
differentiation primary response gene 88 (MyD88) is
recruited to activate the NF-B and MAPK pathways via
TNF receptor-associated factor 6 (TRAF6) and the IL-1
receptor-associated kinases (IRAKs) [29], and a second
pair of Toll-IL-1-resistance (TIR) domain-containing
adaptors inducing interferon-beta (TRIF) and TRIF-
related adaptor molecule (TRAM) induce signaling via
TRAF3 and the interferon regulatory factors (IRFs) to
activate the interferon response [30]. However, there is
growing evidence that other adaptor molecules could
also make important contributions to the inflammatory
responses. The role of p52Shc in transducing signals for
proliferative responses to TCR agonists has been
reported [31] and the negative regulation in T-cell and
B-cell activation via p66Shc using p66
-/- mice has also
been illustrated [19].
The involvement of Shc members in signaling pathways
have been well characterized [17,32,33]. The CH1
domain has three tyrosine residues, 239/240 and 317 in
p52Shc, which upon phosphorylation interact with Grb2
and have been proposed to be differentially coupled to
Fos-dependent proliferation signaling (Y317) and to
Myc-dependent survival pathways (YY239/240) in B-cell
Figure 3 Surface marker measurements of DC phenotype for the effects of Shc blockade on LPS-primed maturation. DCs cultured in
medium only were immature, with relative low expression of MHC-II and co-stimulatory markers CD80 and CD86 (no LPS). The administration of
LPS induced similar levels of DC maturation, indicated by up-regulation of MHC-II, and CD86, in the presence of transfected Shc siRNA (black) or
NEG. siRNA (white) (B and C). However, the co-inhibitory marker CD80 was significantly enhanced when Shc was silenced in LPS-treated DCs
(compared to NEG. siRNA) (A). The lower panel of 3A shows histogram overlay of CD80 expression in control (black), LPS-exposed with NEG.
siRNA (gray) and LPS-exposed with Shc siRNA (light gray) transfection measured by flow cytometry. Each column represents the mean
fluorescence intensity (MFI) ± SE of the three independent experiments (n = 3; **, P < 0.01; *, P < 0.05).
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Page 6 of 12[32] and T-cell activation [34]. In the present study, we
provide new insight into the role of Shc in the matura-
tion process triggered by LPS in DC, and we evaluate
their contribution in the context of LPS-induced TLR4
signaling. The proximal signaling events occurring
through Shc in association with LPS-induced maturation
of DC were first defined. Our study was based on the pri-
mary observation in accumulation of Shc proteins after a
48-h LPS treatment. Strong suppression of IL-6 and IL-
12 production by Shc siRNA as well as anti-Shc mAb in
Figure 4 STAT3 phosphorylation activated by LPS is significantly enhanced by Shc blockade. DCs from Lewis rats were stimulated with
LPS (0.5 μg/ml) in the presence of Shc siRNA (50 nM, 100 nM) or NEG. siRNA. Cells were harvested and Western blot analysis was performed for
phospho-STAT3 at Tyr-705 and for total STAT3. Additional treatment of 10 nM SU6656 indicated total inhibition of STAT3 phosphorylation at Tyr-
705. Each column represents the mean ± SE of the three independent experiments (n = 3; *, P < 0.05).
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Page 7 of 12DC suggests the role of Shc signaling in promoting the
pro-inflammatory properties of LPS-stimulated DC.
However, the Shc-silenced DC stimulated with LPS also
exhibited increased levels of costimulatory molecules and
MHC II antigen stimulation. This indicates that the tol-
erogenic state of LPS-primed DC under Shc silencing
could be determined by unravel factors through IL-10, a
cytokine which has also been found in contributing to
hCG-induced tolerogenic phenotype of DC [35].
Recently, the role of activated STAT3 as the transcription
factor induced by IL-10 in tolerogenic DC was investi-
gated [36,37]. DCs expressing activated STAT3 produce
less IL-12p40 by inhibiting the recruitment but not acti-
vation of NF-B subunits [38]. In this study, we found
that Shc blockade significantly enhances STAT3 phos-
phorylation on tyrosine residue-705 and increases the
nuclear localization of phospho-STAT3 in a Src-depen-
dent manner. This finding establishes a novel signaling
event for STAT3 and associates its activation with a
negative regulatory role for Shc in tolerogenic properties
o fD C .F u r t h e r m o r e ,i th a sb e e nf o u n dt h a tt h eS T A T 3
pathway is required for IL-10-mediated down-regulation
of inflammatory genes in monocytes by LPS [39,40], and
STAT3 phosphorylation is likely due to LPS-induced IL-
10 secretion in DC, while no phospho-STAT3 was
observed in LPS-stimulated IL-10
-/- BMDCs [38]. Our
results are consistent with these studies in that LPS-
induced STAT3 phosphorylation was blocked by IL-10
Figure 5 LPS-induced STAT3 phosphorylation was inhibited by IL-10 neutralizing mAb on DCs. DCs from Lewis rats were stimulated with
LPS (0.5 μg/ml) in the presence of control IgG (Ctrl IgG, 2 μg/ml), anti-IL-10 mAb (2 μg/ml) or anti-IL-10 mAb combined with Shc silencing for 6
h. Cells were harvested and Western blot analysis was performed for phospho-STAT3 at Tyr-705 and for total STAT3. Anti-IL-10 mAb significantly
inhibited the LPS-induced STAT3 phosphorylation in both DCs and Shc-silenced DCs indicated the dependence of secreted IL-10 in STAT3
activation. Each column represents the mean ± SE of the three independent experiments (n = 3; *, P < 0.05).
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Page 8 of 12neutralization. LPS-induced IB degradation was not
affected by Shc blockade and Src inhibitor SU6656 (data
not shown). In conjunction with a similar activation pro-
file for Erk1/2 and p38 signaling events, these data sug-
gest that LPS-triggered Src-Shc signaling events are not
involved directly in the signaling cascade which has been
reported in causing increased IL-12p40 gene expression
via other adaptor proteins through MAPK and NF-B
pathways [39,41]. The TLR-stimulated signaling cascades
via activation of transcription factors NF-B, AP-1 and
IRF3, results in the expression of “innate” genes involved
in pro-inflammatory properties of mature DC were not
determined by Src-family kinase activity. However, the
pro-inflammatory properties of mature DC were directed
to Th2 phenotype and determined by Src-mediated
STAT3 activation while Shc was blocked.
Figure 6 Cell fractionation analysis shows significant increased level of phospho-STAT3 in the nucleus (N) but not cytoplasm (C) on
LPS-treated DCs with Shc silencing. DCs from Lewis rats were stimulated with LPS (0.5 μg/ml) in the presence of Shc siRNA (50 nM) or equal
amount of NEG. siRNA. Nuclei were pelleted and the supernatant was collected as described in Materials and Methods. The cytoplasmic fraction
(C) and the nuclear fraction (N) were analyzed by SDS/PAGE and Western blot for the presence of endogenous STAT3. The phosphorylation
levels of endogenous STAT3 at Tyr-705 were significantly increased in both N and C fractions after LPS treatment for 6 h. However, the
significant enhancement of STAT3 phosphorylation was observed only in the N fraction LPS-treated DCs in the presence of Shc siRNA. Each
column represents the mean ± SE of the three independent experiments (n = 3; *, P < 0.05).
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Page 9 of 12Furthermore, Shc proteins are key components of the
pathways that activate downstream signaling molecules
of growth factor receptors, extracellular matrix proteins
and mechanical forces [16,17,42], and have been
revealed a role in inflammatory signaling with increased
ECM binding [43]. A recent study also showed that
LPS-induced DC is enriched in MHC-II antigen and
intercellular adhesion molecule 1 (ICAM-1) in the vesi-
cular compartment called exosomes [44]. The enriched
MHC-II and ICAM-1 are required for mature DC to
prime naïve T cells representing the immunogenic activ-
ity of LPS-treated DCs. We briefly found that co-immu-
noprecipitation of p52Shc and ICAM-1 in LPS-treated
DCs (data not shown) implying the involvement of
adhesion molecules via Shc in modulating the immuno-
genic and tolerogenic properties of mature DC. How-
ever, the detailed mechanisms for the interplay of
extracellular matrix, adaptor proteins as well as specific
SFKs are critical in the regulation of DC-mediated
immune response and require further investigation.
Conclusions
In summary, we propose a model where the LPS-primed
mature DC produce high level of IL-10 as well as
nuclear transactivation of Src-mediated phospho-STAT3
while Shc-mediated signaling is blocked. Our findings
s u g g e s tt h a tt h eb a l a n c eo fi nflammatory versus anti-
inflammatory cytokines generated by DCs upon TLR sti-
mulation could be critically determined by Shc, which
may act like a switch in response to subsequently
acquired immunity.
Methods
Rat
Four-week-old male Lewis (LEW; RT1
l) rats were
obtained from the National Laboratory Animal Breeding
and Research Center (Taipei, Taiwan). All animals were
maintained in specific pathogen-free animal facilities
with water and commercial rat food provided ad libitum.
Our experimental design was reviewed and approved by
our institutional experimental animal committee.
Preparation, transfection and treatment of bone marrow-
derived dendritic cells
Thigh bones obtained from LEW rats were cleaned of
muscle tissue and placed in sterile Petri dishes containing
complete medium [RPMI-1640 with 10% fetal bovine
serum (FBS), penicillin/streptomycin 100 U/ml and 100
mg/ml and 2 mM L-glutamine], following the procedures
described elsewhere [45]. On day 8, the non-adherent
cells were aspirated for DCs culture. Briefly, the wells
were washed once with medium, and the cells were
pooled. DCs (1 × 10
6 cells) were placed in a new six-well
plate and cultured in fresh DC culture medium (DCM)
containing 50 ng/ml recombinant granulocyte-monocyte
colony-stimulating factor (rGM-CSF), 50 ng/ml rIL-4
(CytoLab, Ltd, Rehovot, Israel) and endotoxin (lipopoly-
saccharide, LPS; 0.5 μg/ml; Sigma, St Louis, MO, USA)
with the addition of anti-Shc monoclonal antibody (mAb,
2 μg/ml) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and mouse IgG (2 μg/ml) (Santa Cruz Biotechnol-
ogy) for 24 h. For transient transfection experiments,
DCs were transfected with 50 nM of Shc siRNA or Silen-
cer
® negative control siRNA (NEG. siRNA) (Ambion
Inc., Austin, TX, USA) using GenMute™ (SignaGen
Laboratories, Gaithersburg, MD, USA) for 24 h.
In some experiments, DCs (1 × 10
6 cells) were treated
with a selective Src family kinase inhibitor SU6656 (10
nM) (Sigma, St. Louis, MO, USA) in the presence of
LPS stimulation with or without Shc blockade.
Cytokine detection in ELISA
After 24-h LPS stimulation of DCs with or without Shc
blockade, supernatants were harvested and assayed for
cytokine production using commercially available ELISA
specifically for the rat IL-12p70 (eBioscience Inc., San
Diego, CA, USA), IL-10 (R&D Systems Inc., Minneapo-
lis, MN, USA) and IL-6 (R&D Systems Inc.) according
to the manufacturer’s instructions.
RNA isolation and real-time PCR
Total RNA was isolated from DCs using the RNeasy kit
from Qiagen (Valencia, CA, USA), according to the
manufacturer’s instructions. Reverse transcripts were
performed using the First-Strand cDNA synthesis kit
(Promega, Madison, WI, USA) following the manufac-
turer’s recommendations. Total RNA (1 μg) was tran-
scribed to cDNA in a 20-μl reaction volume. The
quantitative PCR reaction was performed on an ABI
7500 Fast Real-Time PCR System with the SDS 1.4 pro-
gram and using the ABI TaqMan Fast Universal PCR
master mix (Applied Biosystems, Foster, CA, USA). The
primers and TaqMan MGB probes of IL-10
(Rn00563409_m1) and IL-12 (Rn00575112_m1) were
obtained from Applied Biosystems, and the final concen-
tration of primers and probes was 300 nM and 250 nM,
respectively. The cycling profile for each run was 95°C
for 20 seconds and 40 cycles of 95°C for 3 seconds fol-
lowed by 60°C for 30 seconds, using the default ramp
rate. Normalization was performed by using rat GAPDH
primers. Comparative real-time PCR (RT-PCR) data was
analyzed in triplicate, including non-template controls.
Fold increase in the expression of cytokine mRNA was
calculated by using the comparative 2
ΔCt method.
Antibodies and Western blot analysis
Cell lysates (30-40 μg) were electrophoresed and per-
formed Western blot analysis as previously described [46].
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Page 10 of 12Antibodies to phospho-Shc (Tyr239/240 or Tyr317) and
total Shc, phospho- and total STAT3 were all purchased
from Cell Signaling (Cell Signaling Technology, Inc., Dan-
vers, MA, USA). Antibody to Shc blocking (PG-797) was
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Antibody to IL-10 neutralization (ARC9102)
was purchased from Invitrogen (Carlsbad, CA, USA).
Antibody to a-actin was obtained from Santa Cruz Bio-
technology. Appropriate HRP-conjugated, secondary anti-
bodies were used to visualize the specific bands. Detection
was performed with the Immobilon Western HRP Sub-
strate (Millipore, Billerica, MA, USA), and relevant bands
were quantified by densitometry using UVI photo version
99 and TotalLab software version 1.00 (Nonlinear USA
Inc., Durham, NC, USA).
Nuclear and cytoplasmic protein extraction
DCs with different treatment conditions were washed twice
in PBS, harvested, and pelleted by centrifugation at 500 × g
for 3 min. CERI (NE-PER™, Thermo Fisher Scientific Inc.,
Rockford, IL, USA) was added to each sample following
the supplier’s guideline (200 μlo fC E R Ip e r2 0 - μlc e l l
volume). Briefly, cells were resuspended by vortexing for
15 seconds and then incubated on ice for 10 min. CERII
was then added to each sample (11 μlo fC E R I Is o l u t i o nf o r
every 20-μlc e l lv o l u m e )f o l l o w e db yr e p e a t e dv o r t e x i n g
and centrifugation at 13,000 × g for 5 min. The superna-
tant (cytoplasmic extract) was immediately stored on ice.
The insoluble nuclear pellet was resuspended in 100 μlo f
NER (NE-PER™, Thermo Fisher Scientific Inc.) per 20-μl
cell volume and incubated on ice for 40 min with intermit-
tent brief vortexing. The samples were centrifuged at
13,000 × g for 10 min, and the supernatant (nuclear
extract) was stored on ice. After measuring the total
volumes of each fraction, their protein concentrations were
measured using the Thermo protein assay reagent. All
cytoplasmic and nuclear protein fractions were stored at
-80°C and ready for further Western blot analysis.
FACS analysis
DCs (1 × 10
6 cells/ml) were harvested in RPMI com-
plete medium and were washed twice with PBS con-
taining 0.1% sodium azide plus 2% heat-inactivated
FBS (wash buffer). Cells were incubated with various
mAb [fluorescein isothiocyanate (FITC)-anti-CD80,
FITC-anti-CD86, FITC-anti-MHC class II] at 4°C for
40 min. All the fluorescein-conjugated mAb were
obtained from BD Pharmingen (Franklin Lakes, NJ,
USA) or eBioscience, and isotype-matched Ab used as
controls were purchased from Santa Cruz Biotechnol-
ogy. After extensive washing, the cells were fixed in 4%
paraformaldehyde. Stained DC, gated according to for-
ward- and side-scatter characteristics, were analyzed
on Epics
® ALTRA™ flow cytometer (Beckman
Coulter, Inc., Fullerton, CA, USA) using EXPO32 soft-
ware. Fluorescence data were expressed as percentage
of positive cells compared to immature DCs.
Statistical analysis
The statistical significance of the data was calculated
using Student’s t-test. A value of P <0 . 0 5w a sc o n s i d -
ered to indicate statistical significance.
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